Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Morepen Laboratories
Small Cap•2,152 Employees•IPO 1992
Current Price
₹38.06
0.31 (0.82%)Updated
Today's Range
37.42
₹38.06
38.33
52 Week Range
52W Low₹33.50
52W High₹70.50
₹38.06
Downside13.61%
Upside85.23%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹2,128.8 Cr
Market Cap
Total market value of companyP/E Ratio
20.92
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
2.19
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹1.81
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
5.20%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
15.10%
ROCE
Return on Capital Employed. >15% is goodNet Margin
5.57%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
24.18%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
16.25%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-6.59%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-70.30%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.09
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹21.10
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
35.60%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
3 points- •Morepen Laboratories demonstrates strong operational efficiency with a healthy Return on Equity (ROE) of 11.80% and Return on Capital Employed (ROCE) of 15.10%, indicating effective utilization of capital and shareholder investments for profit generation.
- •The company maintains a very low debt-to-equity ratio of 0.09, signifying a robust financial structure and minimal reliance on borrowed capital, which enhances its financial stability and reduces risk for investors.
Weaknesses
4 points- •Morepen Laboratories experienced a substantial quarterly profit decline of -70.30%, indicating significant operational challenges or market headwinds that could impact short-term earnings stability and investor confidence.
- •The company's quarterly sales growth shows a negative trend of -6.59%, suggesting a potential slowdown in market demand or increased competitive pressures, which warrants further investigation into its revenue generation.
Opportunities
3 points- •Operating in the "Pharmaceuticals" and "Healthcare" sectors, Morepen Laboratories stands to benefit from the inherent growth drivers of these industries, including increasing healthcare spending and demand for new drugs.
- •Despite current challenges, the company's PE ratio of 28.90 is lower than some peers (e.g., Divi's Lab at 74.95), suggesting potential for a valuation re-rating if it can demonstrate sustained profit and sales recovery.
Threats
4 points- •Morepen Laboratories faces significant competition from larger, more established peers like Sun Pharma and Dr Reddy's, which boast higher ROCE and market share, potentially limiting its growth and pricing power.
- •The pharmaceutical industry is subject to stringent regulatory changes and approvals, which could impact Morepen's product development, manufacturing, and market access, posing a continuous operational risk.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹40.27 | +₹2.21 | +5.82% |
| R3 | ₹39.36 | +₹1.30 | +3.42% |
| R2 | ₹38.85 | +₹0.79 | +2.07% |
| R1 | ₹38.45 | +₹0.39 | +1.03% |
| PIVOT | ₹37.94 | -0.12 | -0.32% |
| CURRENT | ₹38.06 | - | - |
| S1 | ₹35.72 | -₹2.34 | -6.14% |
| S2 | ₹36.63 | -₹1.43 | -3.75% |
| S3 | ₹37.03 | -₹1.03 | -2.72% |
| S4 | ₹37.54 | -₹0.52 | -1.36% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-85.4% vs avg
2.02M
(17 Mar 2026)Delivery %+2.3% vs avg
31.1%
(17 Mar 2026)Avg Volume (20D)20-day average
13.88M
(17 Feb - 17 Mar)Avg Delivery %Trend ↓
28.7%
(17 Feb - 17 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Solara Active Pharma Sciences Ltd
178.00 %
Highest Dividend Yield
TTK Healthcare Ltd
1.07 %
Peer Comparison
| Company Name |
|---|
 Amrutanjan Health Care Ltd |
 Beta Drugs Ltd |
 Bliss GVS Pharma Ltd |
 Gufic BioSciences Ltd |
 Hikal Ltd |
 Indoco Remedies Ltd |
 IOL Chemicals & Pharmaceuticals Ltd |
 NGL Fine Chem Ltd |
 SMS Pharmaceuticals Ltd |
 Solara Active Pharma Sciences Ltd |
 Sun Pharmaceutical Industries Ltd |
 TTK Healthcare Ltd |
 Unichem Laboratories Ltd |
About
Morepen Laboratories Ltd
Morepen Laboratories Limited is a multinational company headquartered in Gurugram, India, established in 1984. Their core business revolves around the development, manufacturing, marketing, and sale of a diverse range of healthcare products across several key sectors. This includes a significant presence in the Active Pharmaceutical Ingredients (API) market, providing crucial components for various medications.
A substantial portion of Morepen's business focuses on the production and distribution of APIs. These APIs are used in the creation of pharmaceuticals targeting a wide spectrum of conditions, including allergies (anti-histaminic, anti-asthmatic), cardiovascular issues (anti-lipemic, anti-hypertensive, anti-coagulant), diabetes (anti-diabetic), ulcers (anti-ulcerative), and mental health (anti-depressant). This underscores their significant role in the pharmaceutical supply chain.
Beyond APIs, Morepen Laboratories also manufactures and sells a broad range of home healthcare products. This segment encompasses a considerable selection of diagnostic tools and equipment, such as blood glucose monitors and test strips, blood pressure monitors (sphygmomanometers), digital thermometers, nebulizers, pulse oximeters, and even air purifiers. This comprehensive array of products caters to both professional and personal healthcare needs.
Furthermore, Morepen offers a diverse portfolio of Over-The-Counter (OTC) and healthcare products marketed under the prominent "Dr. Morepen" brand. This includes a wide array of medications and remedies designed to address common ailments like fever, pain, constipation, and acidity. The brand also extends to products focused on specific health areas, encompassing formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, allergy treatment, central nervous system disorders, cardiology, diabetology, and nutraceuticals. This demonstrates a strategic approach to capturing a broad market share across various healthcare segments.
In summary, Morepen Laboratories' business model is multifaceted and encompasses a vertically integrated approach from the production of APIs to the development and marketing of finished pharmaceutical products and home healthcare devices. Their geographical reach extends internationally, with a focus on India and the United States, demonstrating a considerable level of market penetration and a robust business strategy.
COMPANY FACTS - MOREPENLAB
Registered Address
2nd Floor, Tower-C, DLF Cyber Park, Udyog Vihar III, Sector 20,
Gurgaon
HARYANA
IN
Tel: 911244892000
Website:https://www.morepen.com/
Investor Relations:http://www.morepen.com/investors
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 2,152
IPO Date: 16/11/1992
MANAGEMENT - MOREPENLAB
Mr. Sushil Suri
Executive Chairman of the Board, Managing Director
Mr. Ajay Sharma
Chief Financial Officer
Mr. Vipul Srivatava
Compliance Officer, Company Secretary
Mr. Sanjay Suri
Whole-Time Director
Mr. Sharad Jain
Independent Director
Mr. Ranjit Khattar
Independent Director
Dr. Savita ..
Non-Executive Independent Director
Mr. Praveen Dutt
Non-Executive Independent Director
Investor Questions Answered
Morepen Laboratories Ltd (MOREPENLAB) Stock FAQs
Get answers to the most common questions about Morepen Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Morepen Laboratories Ltd (MOREPENLAB) is ₹38.06. Today, the stock has gained by ₹0.31 (0.82%), trading in a range of ₹37.42 to ₹38.33. The stock opened at ₹38 with a trading volume of 20,24,282 shares.
Morepen Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,128.8 crores, P/E ratio of 20.92, ROE of 5.20%, and ROCE of 15.10%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Morepen Laboratories Ltd (MOREPENLAB) is ₹70.5, while the 52-week low is ₹33.5. Currently trading at ₹38.06, the stock is 12.3% away from its 52-week low and 46.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Morepen Laboratories Ltd stock at ₹38.06 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.92 and P/B ratio of N/A. Today's performance shows a gain of 0.82%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Morepen Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹38.06, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Morepen Laboratories Ltd's key financial metrics include: P/E Ratio: 20.92, P/B Ratio: N/A, ROE: 5.20%, ROCE: 15.10%, Dividend Yield: 0.00%, EPS: ₹1.81, Book Value: ₹21.1, Debt-to-Equity: 0.09, and Current Ratio: N/A. The company's market cap stands at ₹2,128.8 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Morepen Laboratories Ltd stock opened at ₹38 and is currently trading at ₹38.06, showing a gain of ₹0.31 (0.82%). The intraday high is ₹38.33 and low is ₹37.42. The trading volume stands at 20,24,282 shares, indicating strong market participation today.
Morepen Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 20.92, which means investors are willing to pay ₹20.92 for every ₹1 of earnings. With an EPS of ₹1.81, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Morepen Laboratories Ltd has a market capitalization of ₹2,128.8 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹38.06) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Morepen Laboratories Ltd has a book value of ₹21.1 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹38.06, which is 80.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Morepen Laboratories Ltd has a Return on Equity (ROE) of 5.20% and Return on Capital Employed (ROCE) of 15.10%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Morepen Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Morepen Laboratories Ltd has a debt-to-equity ratio of 0.09, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Morepen Laboratories Ltd has an Earnings Per Share (EPS) of ₹1.81, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹38.06 and P/E ratio of 20.92, investors are paying 20.92 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Morepen Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Morepen Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Morepen Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (20.92), ROE (5.20%), debt-to-equity (0.09), and growth rates. 2) Technical Analysis - Check 52-week range (₹33.50 - ₹70.50), moving averages, and chart patterns. 3) Valuation - Compare current price (₹38.06) with book value (₹21.10) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Morepen Laboratories Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹38.06 is 1803x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Morepen Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹33.50 - ₹70.50). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.09 indicates leverage. 4) Liquidity Risk - Based on trading volume of 20,24,282 shares. 5) Valuation Risk - P/E of 20.92 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Morepen Laboratories Ltd operates in the industry with key metrics: P/E ratio of 20.92, ROE of 5.20%, market cap of ₹2,128.8 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.09), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Morepen Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹38.06, with a 52-week range of ₹33.50 to ₹70.50. Based on fundamentals like P/E (20.92), ROE (5.20%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Morepen Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹38.06. 2) Fundamental Deterioration - Declining ROE (currently 5.20%), increasing debt (D/E: 0.09), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Morepen Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu